Cancer Therapy with Alpha-Emitters Labeled Peptides

Ekaterina Dadachova

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Actively targeted α-particles offer specific tumor cell killing action with less collateral damage to surrounding normal tissues than β-emitters. During the last decade, radiolabeled peptides that bind to different receptors on the tumors have been investigated as potential therapeutic agents both in the preclinical and clinical settings. Advantages of radiolabeled peptides over antibodies include relatively straightforward chemical synthesis, versatility, easier radiolabeling, rapid clearance from the circulation, faster penetration and more uniform distribution into tissues, and less immunogenicity. Rapid internalization of the radiolabeled peptides with equally rapid re-expression of the cell surface target is a highly desirable property that enhances the total delivery of these radionuclides into malignant sites. Peptides, such as octreotide, α-melanocyte-stimulating hormone analogues, arginine-glycine-aspartic acid-containing peptides, bombesin derivatives, and others may all be feasible for use with α-emitters. The on-going preclinical work has primarily concentrated on octreotide and octreotate analogues labeled with Bismuth-213 and Astatine-211. In addition, α-melanocyte-stimulating hormone analogue has been labeled with Lead-212/Bismuth-212 in vivo generator and demonstrated the encouraging therapeutic efficacy in treatment of experimental melanoma. Obstacles that continue to obstruct widespread acceptance of α-emitter-labeled peptides are primarily the supply of these radionuclides and concerns about potential kidney toxicity. New sources and methods for production of these medically valuable radionuclides and better understanding of mechanisms related to the peptide renal uptake and clearance should speed up the introduction of α-emitter-labeled peptides into the clinic.

Original languageEnglish (US)
Pages (from-to)204-208
Number of pages5
JournalSeminars in Nuclear Medicine
Volume40
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Peptides
Neoplasms
Radioisotopes
Melanocyte-Stimulating Hormones
Octreotide
Therapeutics
Astatine
Kidney
Bombesin
Experimental Melanomas
Bismuth
Tissue Distribution
Aspartic Acid
Glycine
Arginine
Antibodies

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Cancer Therapy with Alpha-Emitters Labeled Peptides. / Dadachova, Ekaterina.

In: Seminars in Nuclear Medicine, Vol. 40, No. 3, 05.2010, p. 204-208.

Research output: Contribution to journalArticle

Dadachova, Ekaterina. / Cancer Therapy with Alpha-Emitters Labeled Peptides. In: Seminars in Nuclear Medicine. 2010 ; Vol. 40, No. 3. pp. 204-208.
@article{86079d888a454507a1c72694f0a5c2eb,
title = "Cancer Therapy with Alpha-Emitters Labeled Peptides",
abstract = "Actively targeted α-particles offer specific tumor cell killing action with less collateral damage to surrounding normal tissues than β-emitters. During the last decade, radiolabeled peptides that bind to different receptors on the tumors have been investigated as potential therapeutic agents both in the preclinical and clinical settings. Advantages of radiolabeled peptides over antibodies include relatively straightforward chemical synthesis, versatility, easier radiolabeling, rapid clearance from the circulation, faster penetration and more uniform distribution into tissues, and less immunogenicity. Rapid internalization of the radiolabeled peptides with equally rapid re-expression of the cell surface target is a highly desirable property that enhances the total delivery of these radionuclides into malignant sites. Peptides, such as octreotide, α-melanocyte-stimulating hormone analogues, arginine-glycine-aspartic acid-containing peptides, bombesin derivatives, and others may all be feasible for use with α-emitters. The on-going preclinical work has primarily concentrated on octreotide and octreotate analogues labeled with Bismuth-213 and Astatine-211. In addition, α-melanocyte-stimulating hormone analogue has been labeled with Lead-212/Bismuth-212 in vivo generator and demonstrated the encouraging therapeutic efficacy in treatment of experimental melanoma. Obstacles that continue to obstruct widespread acceptance of α-emitter-labeled peptides are primarily the supply of these radionuclides and concerns about potential kidney toxicity. New sources and methods for production of these medically valuable radionuclides and better understanding of mechanisms related to the peptide renal uptake and clearance should speed up the introduction of α-emitter-labeled peptides into the clinic.",
author = "Ekaterina Dadachova",
year = "2010",
month = "5",
doi = "10.1053/j.semnuclmed.2010.01.002",
language = "English (US)",
volume = "40",
pages = "204--208",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Cancer Therapy with Alpha-Emitters Labeled Peptides

AU - Dadachova, Ekaterina

PY - 2010/5

Y1 - 2010/5

N2 - Actively targeted α-particles offer specific tumor cell killing action with less collateral damage to surrounding normal tissues than β-emitters. During the last decade, radiolabeled peptides that bind to different receptors on the tumors have been investigated as potential therapeutic agents both in the preclinical and clinical settings. Advantages of radiolabeled peptides over antibodies include relatively straightforward chemical synthesis, versatility, easier radiolabeling, rapid clearance from the circulation, faster penetration and more uniform distribution into tissues, and less immunogenicity. Rapid internalization of the radiolabeled peptides with equally rapid re-expression of the cell surface target is a highly desirable property that enhances the total delivery of these radionuclides into malignant sites. Peptides, such as octreotide, α-melanocyte-stimulating hormone analogues, arginine-glycine-aspartic acid-containing peptides, bombesin derivatives, and others may all be feasible for use with α-emitters. The on-going preclinical work has primarily concentrated on octreotide and octreotate analogues labeled with Bismuth-213 and Astatine-211. In addition, α-melanocyte-stimulating hormone analogue has been labeled with Lead-212/Bismuth-212 in vivo generator and demonstrated the encouraging therapeutic efficacy in treatment of experimental melanoma. Obstacles that continue to obstruct widespread acceptance of α-emitter-labeled peptides are primarily the supply of these radionuclides and concerns about potential kidney toxicity. New sources and methods for production of these medically valuable radionuclides and better understanding of mechanisms related to the peptide renal uptake and clearance should speed up the introduction of α-emitter-labeled peptides into the clinic.

AB - Actively targeted α-particles offer specific tumor cell killing action with less collateral damage to surrounding normal tissues than β-emitters. During the last decade, radiolabeled peptides that bind to different receptors on the tumors have been investigated as potential therapeutic agents both in the preclinical and clinical settings. Advantages of radiolabeled peptides over antibodies include relatively straightforward chemical synthesis, versatility, easier radiolabeling, rapid clearance from the circulation, faster penetration and more uniform distribution into tissues, and less immunogenicity. Rapid internalization of the radiolabeled peptides with equally rapid re-expression of the cell surface target is a highly desirable property that enhances the total delivery of these radionuclides into malignant sites. Peptides, such as octreotide, α-melanocyte-stimulating hormone analogues, arginine-glycine-aspartic acid-containing peptides, bombesin derivatives, and others may all be feasible for use with α-emitters. The on-going preclinical work has primarily concentrated on octreotide and octreotate analogues labeled with Bismuth-213 and Astatine-211. In addition, α-melanocyte-stimulating hormone analogue has been labeled with Lead-212/Bismuth-212 in vivo generator and demonstrated the encouraging therapeutic efficacy in treatment of experimental melanoma. Obstacles that continue to obstruct widespread acceptance of α-emitter-labeled peptides are primarily the supply of these radionuclides and concerns about potential kidney toxicity. New sources and methods for production of these medically valuable radionuclides and better understanding of mechanisms related to the peptide renal uptake and clearance should speed up the introduction of α-emitter-labeled peptides into the clinic.

UR - http://www.scopus.com/inward/record.url?scp=77949897111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949897111&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2010.01.002

DO - 10.1053/j.semnuclmed.2010.01.002

M3 - Article

C2 - 20350629

AN - SCOPUS:77949897111

VL - 40

SP - 204

EP - 208

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 3

ER -